The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).
 
Emerson A. Lim
Stock and Other Ownership Interests - Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Michael Thomas Schweizer
Consulting or Advisory Role - AstraZeneca; PharmaIn; Resverlogix
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); ElevateBio (Inst); Immunomedics (Inst); Immunomedics (Inst); Janssen (Inst); Madison Vaccines, Inc. (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Tmunity Therapeutics, Inc. (Inst); Zenith Epigenetics (Inst)
 
Kim N. Chi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - AstraZeneca; Novartis
 
Rahul Raj Aggarwal
Honoraria - Clovis Oncology
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Axiom Biotechnologies; Clovis Oncology; Dendreon
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); BioXCel therapeutics (Inst); Cancer Targeted Technology (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst)
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Medivation; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Foundation Medicine; Foundation One Inc; Janssen; Lilly; Merck; Nektar; Novartis; Pfizer; Pharmacyclics
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst)
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); ImmunityBio (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst)
 
Edward F. Attiyeh
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
James Greger
Employment - Janssen Research & Development
Stock and Other Ownership Interests - GlaxoSmithKline; Johnson & Johnson
Patents, Royalties, Other Intellectual Property - Janssen Research & Development
 
Shujian Wu
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Pharavee Jaiprasart
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
John Loffredo
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Nibedita Bandyopadhyay
Employment - Janssen Research & Development
Stock and Other Ownership Interests - JNJ
 
Hong Xie
Employment - Johnson & Johnson
Leadership - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
Travel, Accommodations, Expenses - Johnson & Johnson
Other Relationship - Incyte (I)
 
Aaron Richard Hansen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; GlaxoSmithKline; Merck; Novartis
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Neoleukin Therapeutics (Inst); Pfizer/EMD Serono (Inst); Roche/Genentech (Inst)